New review article on the SWENOTECA experience
Surveillance vs. adjuvant therapy of clinical stage I testicular tumors - a review and the SWENOTECA experience. Cohn-Cedermark G, Stahl O, Tandstad T; SWENOTECA. Andrology. 2014 Oct 1. doi: 10.1111/andr.280. [Epub ahead of print] Although clinical stage I (CS I) testicular cancer is highly curable, the optimal management is controversial. The aims of the SWENOTECA studies for CS I non-seminoma (NS) and seminoma (S) have been to reduce treatment intensity while maintaining hi
New articles published by SWENOTECA
In the last months several new articles have been published by or in collaboration with SWENOTECA . One Course of Adjuvant BEP in Clinical Stage I Nonseminoma Mature and Expanded Results from the SWENOTECA group. Ann Oncol. 2014 Aug 11. pii: mdu375. [Epub ahead of print] Tandstad T, Ståhl O, Håkansson U, Dahl O, Haugnes HS, Klepp OH, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Cavallin-Ståhl E, Stierner U, Wahlquist R, Wall N, Cohn-Cedermark G; on behalf of
New protocol for seminoma SWENOTECA IX
A new protocol for seminoma is now available. It replaces SWENOTECA VII from October 1, 2014. The major changes in the guideline are: Stage I: Patients with tumour size 4 cm or less and without invasion of the rete testis are recommended surveillance. Patients with tumour size more than 4 cm or invasion of the rete testis are recommended adjuvant carboplatin. Surveillance may be an option to those patients not wanting adjuvant treatment. Stage II A Chemotherapy in the form
